Log In Sign up
The largest database of trusted experimental protocols

Lovastatin

Manufactured by Bio-Techne
Visit Supplier
Sourced in United Kingdom

Lovastatin is a laboratory compound used in research and development. It is a type of statin, a class of drugs that inhibit the enzyme HMG-CoA reductase, which is involved in the production of cholesterol in the body. Lovastatin is commonly used in scientific studies to investigate the effects of cholesterol regulation and its potential applications.

Automatically generated - may contain errors

Lab products found in correlation

Simvastatin, by Bio-Techne (2 mentions) Mk2206, by Bio-Techne (1 mentions) Ym 53601, by Cayman Chemical (1 mentions) Prism 6, by GraphPad (1 mentions) Celltiter glo assay, by Promega (1 mentions) Multichannel pipette, by Eppendorf (1 mentions) Ggti 298, by Bio-Techne (1 mentions) Verteporfin, by Bio-Techne (1 mentions) Nh125, by Bio-Techne (1 mentions) Amplex red cholesterol assay kit, by Thermo Fisher Scientific (1 mentions) Fcs express 6, by De Novo Software (1 mentions) Accuri c6 flow cytometer, by BD (1 mentions)

5 protocols using lovastatin

1

Comparative Statin Potencies In Vitro

Check if the same lab product or an alternative is used in the 5 most similar protocols
In all experiments, pure forms (≥98.0%) of fluvastatin, lovastatin and simvastatin (Tocris Bioscience) were used. All statins were dissolved in DMSO and tested in final concentrations of 2 and 20 µM.
Chen C., Wu H., Kong D., Xu Y., Zhang Z., Chen F., Zou L., Li Z., Shui J., Luo H., Liu S.H., Yu J., Wang K, & Brunicardi F.C. (2020). Transcriptome sequencing analysis reveals unique and shared antitumor effects of three statins in pancreatic cancer. Oncology Reports, 44(6), 2569-2580.
+ Open protocol
+ Expand
2

Mevalonate Pathway Modulation: A Cell Proliferation Assay

Check if the same lab product or an alternative is used in the 5 most similar protocols
Cells were plated in optical-bottom 96-well plates (Thermo Scientific, Waltham, MA, USA) at a density of 5×103 cells per well. Cells were grown in basal media for 48 hours before 150ml of fresh media was added. Media with maximal drug concentration (simvastatin, lovastatin, GGTI 298, LB 42708, YM-53601) or mevalonate pathway rescue substrates (mevalonolactone, FPP, GGPP) was used to perform serial dilution across wells using a multichannel pipette (Eppendorf, Hamburg, Germany). After 72 hours of treatment, cell numbers were counted by Cell Titer Glo assay (Promega, Madison, WI, USA). Dose-response curves were generated using Graphpad Prism 6 (GraphPad Software, Inc., La Jolla, CA, USA). simvastatin, lovastatin, GGTI 298, LB 42708, verteporfin, and MK-2206 were purchased from Tocris Bioscience, Bristol, UK. YM-53601 was purchased from Cayman Chemical, Ann Arbor, MI, USA.
Theodosakis N., Langdon C.G., Micevic G., Krykbaeva I., Means R.E., Stern D.F, & Bosenberg M.W. (2018). Inhibition of isoprenylation synergizes with MAPK blockade to prevent growth in treatment-resistant melanoma, colorectal, and lung cancer. Pigment cell & melanoma research, 32(2), 292-302.
+ Open protocol
+ Expand
3

Cell Viability Assays for Drug Screening

Check if the same lab product or an alternative is used in the 5 most similar protocols
Cell viability assays were performed on various cell lines following transfection/ nucleofection or pharmacological agent s as described previously [55 (link),56 (link),57 (link)]. Briefly, cells were incubated with various concentrations of NH125 (Tocris, Bristol, UK) or lovastatin (Tocris) for 72 h and treated with MTS for 1-h followed by measuring absorbance at 492 nm. 50–100 μg/mL LDL and 50–100 μM mevalonic acid (Tocris) was added as rescue agents. The IC50 values or percentage of cells for each experimental group were calculated in three independent experiments using GraphPad Prism version 7.04.
Dinavahi S.S., Chen Y.C., Gowda R., Dhanyamraju P.K., Punnath K., Desai D., Berg A., Kimball S.R., Amin S., Yang J.M, & Robertson G.P. (2022). Targeting Protein Translation in Melanoma by Inhibiting EEF-2 Kinase Regulates Cholesterol Metabolism though SREBP2 to Inhibit Tumour Development. International Journal of Molecular Sciences, 23(7), 3481.
+ Open protocol
+ Expand
4

Lovastatin Modulates Cholesterol and Cell Viability

Check if the same lab product or an alternative is used in the 5 most similar protocols
D492 and D492M cells were treated with 5, 10, and 100 µM concentration of lovastatin (Tocris Bioscience, Bristol, UK) for 24 h after which both cholesterol abundance and cell numbers were assessed. The cholesterol was measured using Amplex™ Red Cholesterol Assay Kit (Thermo Fisher Scientific, Waltham, MA, USA) according to manufacturers protocol. The cell numbers were assessed using crystal violet staining. Briefly, after 24 h of treatment, the cells were fixed using ice-cold methanol and stained with crystal violet (0.5%). The stain was subsequently released using 10% acetic acid and absorption was measured at 570 nm.
Karvelsson S.T., Wang Q., Hilmarsdottir B., Sigurdsson A., Moestue S.A., Mælandsmo G.M., Halldorsson S., Gudmundsson S, & Rolfsson O. (2021). Argininosuccinate lyase is a metabolic vulnerability in breast development and cancer. NPJ Systems Biology and Applications, 7, 36.
+ Open protocol
+ Expand
5

Cell Cycle Synchronization and Analysis

Check if the same lab product or an alternative is used in the 5 most similar protocols
Cell cycle progression was assessed following synchronization of cells in G1 phase [37 (link)]. Briefly, 106 MDA-MB-231 cells were seeded in a 100 mm plate for 24 h, followed by 36 h treatment with 10 μM lovastatin (Tocris Bioscience, UK) to achieve synchronization. Cells were released from G1 synchronization by treatment with 1 mM Mevalonate. Cells were harvested and stained with BD Pharmigen PI/RNase staining buffer (BD Biosciences, USA) following manufacturer protocol. Samples were analyzed using a BD Accuri C6 Flow Cytometer (BD Biosciences, USA) and cell cycle distribution was determined using FCS Express 6 Software (De Novo Software, USA).
Nelczyk A.T., Ma L., Gupta A.D., Gamage H.E., McHenry M.T., Henn M.A., Kadiri M., Wang Y., Krawczynska N., Bendre S., He S., Shahoei S.H., Madak-Erdogan Z., Hsiao S.H., Saleh T., Carpenter V., Gewirtz D.A., Spinella M.J, & Nelson E.R. (2022). The nuclear receptor TLX (NR2E1) inhibits growth and progression of triple- negative breast cancer. Biochimica et biophysica acta. Molecular basis of disease, 1868(11), 166515.
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!